Key features and details | |
Cat. No. | MABL-2269 |
Name | Anti-Lipoteichoic acid mAbs |
Clone No. | AFD- BSYX-A110 (Pagibaximab) |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | therapeutic, ELISA |
Species Reactivity | Gram Positive Bacteria |
Basic Information | |
Specificity | This antibody targets the lipoteichoic acid (LTA) which is a major cell wall component of gram positive bacteria. LTA plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. This antibody is also reported to bind whole bacteria for e.g. S. epidermidis (types I, II & III), S. hemolyticus, S. hominus, and two serotypes of S. aureus but not to gram negative bacteria like E. coli. |
Alternative Name | LTA; Staphylococcus epidermidis lipoteichoic acid |
UniProt | |
Immunogen | The original antibody was generated by immunizing mice with whole bacteria strain Hay Streptococcus epidermidis. |
Application Notes | This antibody is also known as PMAB, A110 and Hu96-110. This humanized chimeric antibody is derived from murine antibody M110 and is reported to bind whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. It was originally developed for the prevention of staphylococcal sepsis in infants with low body weight. The serum half-life of the antibody for VLBW infants was 20.5 ± 6.8 days. Pagibaximab enhanced serum opsonophagocytic activity in infants with no signs of immunogenecity of pagibaximab. All staphylococci causing sepsis were opsonizable by pagibaximab (PMID:19380597). Another study reported that three once- a-week 90 or 60 mg/kg pagibaximab infusions, in high-risk neonates, seemed safe and well tolerated (PMID: 21788224). |
Antibody First Published | Weisman et al. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr. (2007); 14 Suppl 1:S31-4. PMID:17939955 |
Note on publication | Describes the potential use of this antibody in the prevention and treatment of neonatal noscocomial staphylococcal infections. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
